50results about How to "Achieve anti-tumor effect" patented technology

The invention relates to an anti-tumor pharmaceutical composition and a preparation method thereof, and belongs to the technical field of bio-pharmaceuticals. The pharmaceutical composition comprises the following components: 20 to 60 percent of extract of brown heart rot of cinnamomum kanehirai, 5 to 30 percent of glossy ganoderma extract and 20 to 60 percent of grifola frondosa extract. The preparation method comprises the following steps: preparing the extract of the brown heart rot of the cinnamomum kanehirai; preparing the glossy ganoderma extract; preparing the grifola frondosa extract; and mixing the extract of the brown heart rot of the cinnamomum kanehira, the glossy ganoderma extract and the grifola frondosa extract. The anti-tumor pharmaceutical composition is an immunopotentiator, has no toxic and side effect, and mainly achieves the anti-tumor effect by reinforcing the immunological competence of the human body. The anti-tumor pharmaceutical composition has reasonable compatibility, and all the components are from natural products, so that the anti-tumor pharmaceutical composition is safe and has no toxic and side effect. The tumor inhibition rate of the anti-tumor pharmaceutical composition is 26.16 percent (P is less than 0.05) and is equivalent to that of the prior anti-cancer medicine cyclophosphamide, but the toxicity of the anti-tumor pharmaceutical composition is obviously lower than that of the cyclophosphamide. The preparation method for the anti-tumor pharmaceutical composition has reasonable design, simple and convenient operation and high extraction purity.

The invention discloses dandelion tea as well as a preparation method and application thereof. The dandelion tea is prepared from the following raw materials in parts by weight: 70-85 parts of dandelions, 15-25 parts of green tea, 0.5-3 parts of liquorice roots and 0.5-3 parts of honey. The raw materials further comprise 0-2 parts of mung beans, 0-2 parts of wolfberry fruits, 0-1 parts of artemisia vulgaris, 0-2 parts of honeysuckles, 0-2 parts of wild chrysanthemum flowers and 0-2 parts of sweet-scented osmanthus. The dandelion tea disclosed by the invention adopts the formula above, and the green tea and the liquorice roots are added, so that the soup color can be changed, and the effect of the dandelion tea can also be added; and the honey is added so that the taste of the dandelion tea can be changed and the storage time can also be guaranteed. All the components are coordinated and matched, so that the dandelion tea has the effects of nourishing liver and prompting choleresis, diminishing inflammation and clearing away heat, clearing away internal heat and detoxifying, improving eyesight and removing acnes, maintaining beauty and keeping young; furthermore, the dandelions contain a plurality of types of sugars and have a relatively strong capability of activating macrophages, so that the dandelion tea has the effects of resisting tumors after being drunk for a long period, and particularly has relatively good effects on constipation and mastosis of females.

The invention discloses an N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative and its synthetic method and use. The sialic acid (alpha-(2-6))-D-amino pyranose derivative shown in the formula (I) is synthesized from raw materials of D-galactosamine (glucose) and sialic acid and is coupled with a carrier protein or a polypeptide to form a glycoprotein (glycopeptide) conjugate. In a structure of the N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative, a derivative acyl group replaces an acetyl group and thus the structure is novel. The N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative has good activity in anti-tumor vaccines. A result of an experiment on mice shows that through structural derivatization, a carbohydrate antigen based vaccine can produce an effective immune response and a mass of antibodies and IgG / IgM is improved obviously. The antibodies can identify specifically tumor cells expressing STn and thus anti-tumor effects are realized. STn antigens can be expressed on multiple tumors and thus the N-acyl group modified sialic acid (alpha-(2-6))-D-amino pyranose derivative has a wide application scope.

The invention discloses a recombinant influenza virus rescue method and an application of the same in tumor therapy. The method for preparing recombinant viruses that express antibodies to anti-tumorprotein or contain coding genes of fusion protein includes that single-stranded coding genes, heavy-strained coding genes an / or light-stranded coding genes of anti-tumor protein antibodies are savedby viruses to obtain recombinant viruses with single-stranded, heavy-stranded and / or light-stranded coding genes of anti-tumor protein antibodies and other transforming growth factor receptor or extracellular domain coding genes of the receptor. The recombinant viruses expressing immune checkpoint suppress antibodies are designed; the heavy and light chains encoding immune checkpoint suppress antibodies are constructed in the HA region and NA region of PR8 viruses respectively, and the recombinant oncolytic influenza viruses are constructed to express anti-pd1 anti-pd-L1 antibodies. The oncolytic recombinant influenza viruses provided can target and kill tumor cells without obvious impact on normal host cells and can be used for targeted tumor therapy.

The invention discloses a preparation for improving organism immunity and preventing tumors. 100-220 parts of paecilomyces hepialid powder, 60-180 parts of ganoderma lucidum sporocarp extract and 60-180 parts of agaricus blazei murill sporocarp extract are adopted, mixed, granulated, filled or packaged to prepare capsules or granules. The preparation has the beneficial effects that the paecilomyces hepialid powder, the ganoderma lucidum sporocarp extract and the agaricus blazei murill sporocarp extract can improve the non-specific immunity and specific immunity of human bodies to different levels; furthermore, various diseases related to low immunity are prevented and controlled, and the paecilomyces hepialid powder has a strong function of swallowing tumor cells; the agaricus blazei murill is rich in selenium substance and cancer inhibition substance and has an obvious function of inhibiting various tumor cells; and various ingredients such as ganoderma lucidum can directly inhibit the cancer cell growth so as to realize an anticancer effect. The preparation is synthesized by three ingredients, and has enhanced effects of improving the organism immunity and preventing tumors.

The present invention provides an application of a zkscan3 gene or a protein modifier thereof in tumor therapy and particularly relates to a use of an inhibitor of the ZKSCAN3. The inhibitor of the ZKSCAN3 is used for preparation of a pharmaceutical composition promoting plasmocyte differentiation and proliferation, and / or treating tumors. The application provides a theoretical reference for a treatment strategy of selective knocking-out of the ZKSCAN3 in hematological tumors clinically, and has great significance for the clinical treatment of the hematological tumors targeting the ZKSCAN3.

The invention discloses a recombinant ubiquitin ligase PTB-U-box fusion gene and an expression vector and application thereof. The recombinant ubiquitin ligase PTB-U-box fusion gene is formed by connecting a PTB domain gene of IRS-1 and a U-box domain gene of carboxy terminus of Hsc70 Interacting protein (CHIP), and the specific nucleotide sequence is shown as SEQ ID No. 1. The constructed PTB-U-box fusion gene can be cloned to different expression vectors so as to enter tumor cells through different paths to play a role, and the expression vectors comprise eukaryotic expression vectors or adenovirus expression vectors. After the fusion gene transfects the tumor cells, the carcinogenic related protein IGF-1R of the host tumor cells can be regulated down, the cell proliferation and intrusion capacities of the tumor cells are remarkably reduced, and the fusion gene shows proliferation inhibition and intrusion inhibition on the tumor cells so as to achieve the anti-tumor effect.

The invention relates to application of Kukoamine in preparing anti-tumor drugs, in particular to application of Kukoamine in preparing a PD-1 / PD-L1 axis inhibitor, and belongs to the field of biologic medicine. The inhibitor is used for inhibiting combination of PD-1 / PD-L1, and the effective ingredient of the inhibitor is Kukoamine. The traditional Chinese medicine micromolecule Kukoamin is adopted as the PD-1 / PD-L1 axis inhibitor for the first time, combination of PD-1 / PD-L1 is inhibited, recognition and killing for tumor cells of immune cells, particularly T cells are brought into play, then, the anti-tumor effect is achieved, and the new drug selection is supplied to tumor prevention and / or treatment.

The invention relates to the technical field of food additives and discloses an antioxidant natural food additive. The antioxidant natural food additive is made of, by weight, 5-10 parts of perilla frutescens, 10-18 parts of rutin, 13-20 parts of lentinan and 2-8 parts of catechin. The antioxidant natural food additive is prepared by combination of the perilla frutescens, the rutin, the lentinan and the catechin and is simple in preparation process. Furthermore, when the antioxidant natural food additive is used for making of fried food, stewed food, cakes, canned food, beverages and the like, remarkable antioxidant, bacteriostatic and preservative effects can be achieved while blood pressure reduction, blood fat reduction and anti-tumor functions can be realized .

The invention belongs to the field of medical biology, and particularly relates to a CAR carrier for killing gastric cancer cells by combining an MSLN single-chain antibody and PD-1 mAb, and a construction method and application thereof. The CAR carrier comprises an MSLN single-chain antibody and PD-1 mAb, and the CAR structure is CD8 leader-MSLNscfv-CD8 alpha-CD137-CD3 zeta-IRES-PD-1 mAb, CAR-T cells are obtained through virus infection, and the gastric cancer cells of positive expression of MSLN are identified and killed by expressing the CAR structure. PD-1 mAb binds to PD-1 on the surfaceof T cells and blocks the binding of PD-1 and PD-L1, so that the growth and proliferation of T cells are upregulated, and CAR-T cells show stronger tumor cell killing ability.

The invention relates to a preparation method and application of cationization lentinan. The cationization lentinan can be used as a gene vector delivery system, plays an immunoregulation effect, and effectively solves the application problem in tumor treatment. The invention adopts a technical scheme: the lentinan is connected with low-molecular-weight polyethyleneimine by virtue of a pH sensitive chemical bond, the molecular weight of the lentinan is 20 to 800 kD, the molecular weight of the polyethyleneimine is 600 to 1200 D, and a molar ratio of the polyethyleneimine to the lentinan is 1 : (3 to 10). The preparation process is simple, the sources of raw materials are wide, the cost is low, and the development and application prospect is promising; the prepared cationization lentinan is uniform in shape, the particle size is about 200 nm and is uniform in distribution, the structure is stable, the biological compatibility is good, nucleic acid can be effectively loaded and delivered to tumor cells, and an antitumor effect combining gene therapy and immunotherapy is realized.

The invention discloses a non-natural amino acid short peptide and application thereof in tumor resistance. The amino acid sequence of the non-natural amino acid short peptide is shown as {D-Tyr(Me)}-Asp-Dpr-Asn-{D-Glu}-Thr-Cha. The non-natural amino acid oligopeptide can be synthesized by adopting an existing conventional method. The short peptide can inhibit proliferation and migration of tumor cells, achieves an anti-tumor effect, and does not harm the activity of normal cells. Therefore, the non-natural amino acid short peptide can be used for preparing antitumor drugs for treating esophageal cancer, lung cancer, liver cancer, breast cancer, prostate cancer, gastric cancer, colorectal cancer and other malignant tumors.

The invention relates to an anti-tumor pharmaceutical composition and a preparation method thereof, and belongs to the technical field of bio-pharmaceuticals. The pharmaceutical composition comprises the following components: 20 to 60 percent of extract of brown heart rot of cinnamomum kanehirai, 5 to 30 percent of glossy ganoderma extract and 20 to 60 percent of grifola frondosa extract. The preparation method comprises the following steps: preparing the extract of the brown heart rot of the cinnamomum kanehirai; preparing the glossy ganoderma extract; preparing the grifola frondosa extract;and mixing the extract of the brown heart rot of the cinnamomum kanehira, the glossy ganoderma extract and the grifola frondosa extract. The anti-tumor pharmaceutical composition is an immunopotentiator, has no toxic and side effect, and mainly achieves the anti-tumor effect by reinforcing the immunological competence of the human body. The anti-tumor pharmaceutical composition has reasonable compatibility, and all the components are from natural products, so that the anti-tumor pharmaceutical composition is safe and has no toxic and side effect. The tumor inhibition rate of the anti-tumor pharmaceutical composition is 26.16 percent (P is less than 0.05) and is equivalent to that of the prior anti-cancer medicine cyclophosphamide, but the toxicity of the anti-tumor pharmaceutical composition is obviously lower than that of the cyclophosphamide. The preparation method for the anti-tumor pharmaceutical composition has reasonable design, simple and convenient operation and high extractionpurity.

The invention discloses gemcitabine-aromatic chlormethine conjugate targeting at high-level ROS (reactive oxygen species) of cancer cells and its pharmaceutically acceptable salts, having a structureshown in the general formula I that is shown in the description. The compounds herein can selectively release gemcitabine-aromatic chlormethine conjugate in high-concentration ROS tumor cells, can selectively inhibit the proliferation of tumor cells, can slowly release gemcitabine and aromatic chlormethine further through various esterases or amidases so as to promote the generation of ROS in tumor cells and provide coordinative tumor resistance. The compounds herein can significantly enhance lipid solubility of gemcitabine, can enter cells with no dependence on nucleoside transporter proteins, allows N4-site amino groups of gemcitabine to be less degraded by deaminases, and can improve in-vivo bioavailability of gemcitabine and reduce tolerance of tumor cells to gemcitabine drugs.

The invention provides preparation and a construction method of a CAR-T carrier applied in a colon cancer treatment. The provided treatment carrier is composed of two parts: a slow virus expression vector Pcdh-CMV-MCS-EF1-Puro and a CAR expression structure. The CAR structure is CD8leader-EpCAMscfv-CD8[alpha]-CD28-CD137-CD3[zeta]-IRES-PD-1mAb. The provided treatment carrier and package plasmids (PSPAX2 and pMD2G) are packed to form a three plasmid package system, the ratio of PSPAX2 to pMD2G is 8:1, the ratio of PSPAX2 and pMD2G to carrier plasmid is 3:2, and the three plasmid package system is used to infect 293T cells to obtain CAR-T cells. The provided CAR-T cell can target, identify and kill colon cancer cells with EpCAM positive expression.

The invention belongs to the technical field of medicine application of plant polysaccharide and discloses the application of Japanese ginseng polysaccharide to the preparation of a medicine for improving immunologic function of patients suffering from liver cancer. The invention discovers for the first time that the Japanese ginseng polysaccharide can obviously inhibit in-vivo growth of H22 livercancer cells under a certain dosage, and the Japanese ginseng polysaccharide obviously increases the proportion of CD8+T and NK cells by increasing thymus / spleen index of the organism and spleen cellproliferation and enhances the cytotoxic activity on the liver cancer H22 tumor cells. The Japanese ginseng polysaccharide can stimulate immune response of the mouse organism to exert the anti-tumoreffect, and the toxicity on the tumor-bearing mouse is not detected. The related action mechanism comprises the followings: the Japanese ginseng polysaccharide can improve the ability of tumor transplantation induced CD4+T cell apoptosis; the immunostimulation factor level in the tumor-bearing mouse is increased and the immunosuppression factor level is reduced; the tumor-bearing mouse CD4+T cellsare promoted to be differentiated into Th1 to take part in anti-tumor immunostimulation activity; and the immunostimulation activity is generated by resisting inflammation and adjusting polarizationof TAMs, so that the anti-tumor effect is achieved.

The invention relates to an anti-tumor plant extract composition and a preparation method and application thereof. The plant extract composition is prepared from the following components in percentage by weight: 20-45% of asparagus filicinus extract, 15-35% of youngia extract, 20-40% of herba scutellariae barbatae extract and 5-20% of radix astragali extract. The pharmacological experiments indicate that the plant extract composition provided by the invention has a major function. Moreover, the preparation method of the plant extract composition provided by the invention realizes controllable quality and high content of active ingredients, and is suitable for industrial production.

The invention provides application of canagliflozin in preparation of anti-tumor medicines, particularly provides application of canagliflozin in preparation of medicines for treating solid tumors. Researches prove that canagliflozin has a remarkable effect of reducing immune checkpoint protein PD-L1 in multiple tumor cells, and can effectively reinforce the killing effect of a T cell on tumor cells in a T cell and tumor cell co-incubation model, so that the clinical application of chemical drug canagliflozin in tumor immunotherapy can be expanded.

The invention discloses a garlic antitumor active polypeptide. A preparation method of the garlic antitumor active polypeptide comprises the following steps: carrying out alkali extraction on garlic powder to obtain garlic protein extract, adding protease to the garlic protein extract, carrying out enzymatic hydrolysis to obtain an enzymatic hydrolysate, and carrying out ultrafiltration, gel column chromatography and high performance liquid chromatography on the enzymatic hydrolysate to obtain the garlic polypeptide active substance. The active polypeptide has the advantage of high purity, high quality, high activity and good antitumor effect, and the preparation method of the active polypeptide has the advantages of simplicity, feasibility, low cost, stable process, removal of a large amount of salts, and high yield.

The invention relates to the field of antitumor food, in particular to application and a preparation method of roe polypeptide. The application refers to application of the roe polypeptide in preparation of antitumor and tumor prevention and treatment food. The preparation method of the roe polypeptide comprises the steps as follows: 1) collection of roe cells; 2) thorough cleaning, cell homogenization, freezing and thawing, sedimentation, taking of supernatant, interception and impurity removal and detection treatment of the roe cells; 3) preparation of a roe polypeptide stock solution; and 4) preparation of roe polypeptide powder, mother liquor or solution. Roes play antitumor and anticancer functions by the inhibition effect on melanoma and tumor. Fish byproducts are efficiently utilized in medicines and food and create social benefits for economic development. Compared with a traditional antitumor drug preparation, as bioactive peptides naturally exist in the roe polypeptide stocksolution obtained by roe extraction, the components of the roe polypeptide have certain safety, as an antitumor drug or health food, the roe polypeptide has safety and reliability higher than that oftraditional antitumor drug preparation.

The present invention discloses an anti-tumor small molecule polypeptide targeting FGFRs and an application of the anti-tumor small molecule peptide. An amino acid sequence of the anti-tumor small molecule peptide targeting the FGFRs is as follows: FPDSLYSSLFQL. The anti-tumor small molecule polypeptide can specifically bind to FGFR2, blocks an FGFRs signaling pathway, and achieves an anti-tumor effect. Therefore, the anti-tumor small molecule polypeptide can be used to prepare anti-tumor drugs or tumor diagnostic reagents for diagnosis or treatment of esophageal squamous carcinoma, stomach cancer, breast cancer, prostate cancer, melanoma, etc.

The invention belongs to the technical field of medicines, and in particular relates to a camptothecin glycoconjugate and its preparation method and application. The invention provides a camptothecin glycoconjugate, and the camptothecin glycoconjugate is synthesized by linking camptothecin and hexose with adipic acid as a linker. Experimental results show that the camptothecin glycoconjugate has an anti-tumor effect, and has high efficiency and low toxicity compared with camptothecin. GLUT1 is widely distributed on the blood-brain barrier and red blood cells. The experimental results show that the camptothecin glycoconjugates of the present invention can be recognized and transported by GLUT1, and enter into tumor cells through the GLUT1 pathway to achieve anti-tumor effects. Moreover, the camptothecin glycoconjugates of the present invention Glycoconjugates, as a cytotoxic quinoline alkaloid, can inhibit DNA topoisomerase (TOPO I).

The invention relates to a dendrimer-coated gold nanoparticle composite material and preparation and application thereof, a fifth-generation polyamide-amine dendrimer is used as a carrier, chelating and targeting molecules are modified on the surface of the carrier, then gold nanoparticles are coated by an in-situ reduction synthesis method, and finally CpG is loaded to obtain the dendrimer-coated gold nanoparticle composite material. The preparation process is short in period, the material is low in toxicity under the use dosage and good in biocompatibility, PET / CT bimodal imaging can be achieved, the anti-tumor immune response can be achieved, and potential clinical application value is achieved.

The invention provides a PD-1 blocking agent and application thereof, and belongs to the technical fields of medical science and biochemistry. The PD-1 blocking agent has an amino acid sequence shownin SEQ ID No.1. The provided PD-1 blocking agent can be effectively bonded with PD-1 on PBMCs to block bonding of the PD-1 and PDL1, block the PBMCs, inhibit the activity of immune checkpoints, release immune brakes in a tumor microenvironment, and improve the killing effect of immune cells on tumors, thereby achieving the anti-tumor effect.

The invention discloses a compound, a prodrug thereof or use of a medicinal salt of the compound in preparing an anti-tumor drug. The compound has the following structure (described in the following description).

The invention discloses a recombinant ubiquitin ligase PTB-U-box fusion gene and an expression vector and application thereof. The recombinant ubiquitin ligase PTB-U-box fusion gene is formed by connecting a PTB domain gene of IRS-1 and a U-box domain gene of carboxy terminus of Hsc70 Interacting protein (CHIP), and the specific nucleotide sequence is shown as SEQ ID No. 1. The constructed PTB-U-box fusion gene can be cloned to different expression vectors so as to enter tumor cells through different paths to play a role, and the expression vectors comprise eukaryotic expression vectors or adenovirus expression vectors. After the fusion gene transfects the tumor cells, the carcinogenic related protein IGF-1R of the host tumor cells can be regulated down, the cell proliferation and intrusion capacities of the tumor cells are remarkably reduced, and the fusion gene shows proliferation inhibition and intrusion inhibition on the tumor cells so as to achieve the anti-tumor effect.

The present invention relates to a novel heterocyclic arylhydrazone derivative, its pharmaceutically acceptable salt, its preparation method and application. Construct; In the general structural formula I, R represents an aromatic hydrocarbon, a heterocyclic ring or a substituent having both an aromatic hydrocarbon and a heterocyclic ring; R 1 is a heterocycle. The present invention adds a heterocycle such as thiophene to one side of the hydrazone, and introduces at least one pyridine group on the carbon atom on the other side. These parts are all drug active groups in different fields, and these targets are passed through The specific connection relationship makes it a whole, forming a new drug, which has excellent anticancer activity, and has little toxic and side effects. Its synthesis is simple and convenient, and it is preferably applied in industrial production.

The invention discloses an anti-tumor small molecule polypeptide and its application. The amino acid sequence of the anti-tumor small molecule polypeptide is as follows: LQLQAEER. The anti-tumor small molecule polypeptide can specifically bind to FGFR2, block FGFRs signaling pathway, and achieve anti-tumor effect. Therefore, it can be used to prepare antitumor drugs.

The invention relates to a docetaxel derivative, and a preparation method and application thereof, belonging to the technical field of medicine. The docetaxel derivative provided by the invention is triphenyl phosphine-docetaxel (TD) and is prepared by subjecting docetaxel and 4-carboxybutyltriphenylphosphonium bromide to an esterification reaction under the catalysis of EDC and DMAP. Docetaxel and a mitochondrion-targeted group triphenylphosphine are connected via an ester bond; and the structure of the docetaxel derivative is as shown in the specification. The docetaxel derivative provided by the invention is simple and practicable to synthesize and provides a novel idea for mitochondrion-targeted drug delivery. The docetaxel derivative is entrapped in liposome; the preparation method issimple and practicable and has good reproducibility and high stability; and the PEG-modified liposome of the docetaxel derivative is increased in circulation time in blood and can better release antitumor drugs at tumor sites due to a pH-sensitive fracture mechanism.